PL EN
PRACA POGLĄDOWA
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Wprowadzenie i cel:
Witamina D, pochodząca ze słońca, jest niezbędna dla zachowania wielu funkcji fizjologicznych organizmu człowieka. Niemniej jednak niedobór witaminy D jest zjawiskiem powszechnym i może mieć poważne konsekwencje dla zdrowia psychicznego. Coraz więcej badań poświęcono istniejącym powiązaniom między witaminą D a depresją i zaburzeniami lękowymi oraz ocenie znaczenia tej witaminy w etiologii tych zaburzeń, a także potencjalnych możliwości wykorzystania witaminy D w ich leczeniu. Celem pracy jest usystematyzowanie wiedzy na temat związku witaminy D z depresją i zaburzeniami lękowymi oraz przegląd badań klinicznych oceniających możliwości wykorzystania witaminy D w leczeniu wspomnianych zaburzeń.

Opis stanu wiedzy:
Z przeglądu wynika, że witamina D może w różny sposób wpływać na występowanie i przebieg zaburzeń depresyjnych i lękowych oraz może znaleźć zastosowanie w ich leczeniu. Na dowód tego przywołano kilka badań klinicznych, które potwierdziły zarówno związek witaminy D z objawami depresji i lęku, jak i jej skuteczność w leczeniu tych chorób, szczególnie w połączeniu z innymi lekami. Uzyskane wyniki kliniczne nie są jednak w pełni spójne, co można wiązać z występowaniem czynników zakłócających oraz złożoną etiologią chorób psychicznych.

Podsumowanie:
Konieczne są dodatkowe badania w celu pełnego zrozumienia przyczyn depresji i lęku, zbadania potencjału witaminy D i oceny jej terapeutycznej roli we wspomaganiu leczenia wspomnianych zaburzeń. Badania te powinny uwzględniać złożoność etiologii zaburzeń psychicznych, nasilenie objawów oraz wpływ czynników środowiskowych i genetycznych, w tym indywidualne reakcje na leczenie witaminą D.


Introduction and objective:
Sun-derived Vitamin D is vital for diverse physiological functions. Nevertheless, vitamin D deficiency is common and can have serious consequences for mental health. Ongoing research explores the connections between vitamin D deficiency and depression and anxiety disorders, its role in their development and potential therapeutic uses. The aim of the study is to investigate the role of vitamin D in depression and anxiety disorders, and review clinical studies on its potential therapeutic use in treating these conditions.

Brief description of the state of knowledge:
The review concludes that vitamin D may influence the occurrence and course of depression and anxiety disorders in various ways, and may find application in their treatment. As evidence of this, several clinical studies have confirmed both the association of vitamin D with symptoms of depression and anxiety and its effectiveness in treating these diseases, especially when combined with other medications. However, there is a lack of complete consistency in the clinical results obtained, which may be attributed to the presence of confounding factors and the complex etiology of mental illnesses.

Summary:
Additional research is required to comprehend the causes of depression and anxiety, explore vitamin D›s potential, and conduct thorough investigations into its therapeutic role as an adjunct in treating these disorders. This research should consider the complexities of psychiatric disorder origins, symptom severity, and the impact of environmental and genetic factors, including individual responses to vitamin D treatment.

 
REFERENCJE (53)
1.
Holick MF, Ultraviolet B Radiation: the vitamin D connection. Adv Exp Med Biol. 2017;996:137–154.
 
2.
Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 2016;96(1):365–408.
 
3.
Mazahery H, von Hurst PR. Factors affecting 25-hydroxyvitamin D concentration in response to vitamin D supplementation. Nutrients. 2015;7(7):5111–4512.
 
4.
Bahrami A, Sadeghnia HR, Tabatabaeizadeh SA, et al. Genetic and epigenetic factors influencing vitamin D status. J Cell Physiol. 2018;233(5):4033–4043.
 
5.
Bouvard B, Annweiler C, Salle A, et al. Extraskeletal effects of vitamin D: facts, uncertainties and controversies. Joint Bone Spine. 2011;78(1):10–16.
 
6.
Eyles DW, Smith S, Kinobe R, et al. Distribution of the Vitamin D Receptor and 1a-Hydroxylase in Human Brain. J Chem Neuroanat. 2005;29(1):21–30.
 
7.
Baeke E, Takiishi T, Korf H, et al. Vitamin D: Modulator of the Immune System. Curr Opin Pharmacol. 2010;10(4):482–496.
 
8.
Zhang Z, Yang X, Jia Y, et al. Vitamin D and the Risks of Depression and Anxiety: An Observational Analysis and Genome-Wide Environment Interaction Study. Nutrients. 2021;13(10):3343.
 
9.
Grimm MOW, Lauer AA, Grösgen S, et al. Profiling of Alzheimer’s disease related genes in mild to moderate vitamin D hypovitaminosis. J Nutr Biochem. 2019;67:123–137.
 
10.
Sun W, Maffie JK, Lin L, et al. DPP6 establishes the A-type K(+) current gradient critical for the regulation of dendritic excitability in CA1 hippocampal neurons. Neuron. 2011;71(6):1102–1115.
 
11.
Cacace R, Heeman B, Van Mossevelde S, et al. Loss of DPP6 in neurodegenerative dementia: A genetic player in the dysfunction of neuronal excitability. Acta Neuropathol. 2019;137:901–918.
 
12.
Marini F, Bartoccini E, Cascianelli G, et al. Effect of 1alpha,25- dihydroxyvitamin D3 in embryonic hippocampal cells. Hippocampus. 2010;20(6):696–705.
 
13.
Purves KL, Coleman JRI, Meier SM, et al. A major role for common genetic variation in anxiety disorders. Mol Psychiatry. 2020;25(12):3292–3303.
 
14.
Kendler KS, Gatz M, Gardner CO, et al. A Swedish national twin study of lifetime major depression. Am J Psychiatry. 2006;163:109–114.
 
15.
Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci. 2009;11(3):239–255.
 
16.
Nakajo T, Katayoshi T, Kitajima N, et al. 1,25-Dihydroxyvitamin D3 attenuates IL-1ß secretion by suppressing NLRP1 inflammasome activation by upregulating the NRF2-HO-1 pathway in epidermal keratinocytes. Redox Biol. 2021;48:102203.
 
17.
Yamini P, Ray RS, Chopra K. Vitamin D3 attenuates cognitive deficits and neuroinflammatory responses in ICV-STZ induced sporadic Alzheimer›s disease. Inflammopharmacology. 2018;26:39–55.
 
18.
Neveu I, Naveilhan P, Baudet C, et al. 1,25-Dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF MRNA in astrocytes. Neuroreport. 1994;6(1):124–126.
 
19.
Xu Y, Liang, L. Vitamin D3/Vitamin D receptor signaling mitigates symptoms of post-stroke depression in mice by upregulating hippocampal BDNF expression. Neurosci Res. 2021;170:306–313.
 
20.
Naveilhan P, Neveu I, Wion D, et al. 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport. 1996;7(13):2171–2175.
 
21.
Neveu I, Naveilhan P, Jehan F, et al. 1,25-Dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res Mol Brain Res. 1994;24:70–76.
 
22.
Jiang P, Zhang LH, Cai HL, et al. Neurochemical effects of chronic administration of calcitriol in rats. Nutrients. 2014;6:6048–6059.
 
23.
Luthold RV, Fernandes GR, Franco-de-Moraes AC, et al. Gut microbiota interactions with the immunomodulatory role of vitamin D in normal individuals. Metabolism. 2017;69:76–86.
 
24.
Alghamdi S, Alsulami N, Khoja S, et al. Vitamin D supplementation ameliorates severity of major depressive disorder. J Mol Neurosci. 2020;70:230–235.
 
25.
Bicikova M, Duskova M, Vitku J, et al. Vitamin D in anxiety and affective disorders. Physiol Res. 2015;64:S101–S103.
 
26.
Hoogendijk WJ, Lips P, Dik MG, et al. Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry. 2008;65(5):508–512.
 
27.
Lee DM, Tajar A, O’Neill TW, et al. Lower vitamin D levels are associated with depression among community-dwelling European men. J Psychopharmacol. 2011;25(10):1320–1328.
 
28.
Kjaergaard M, Waterloo K, Wang CE, et al. Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomised clinical trial. Brit J Psychiatry. 2012;201(5):360–368.
 
29.
Song BM, Kim HC, Rhee Y, et al. Association between serum 25-hydroxyvitamin D concentrations and depressive symptoms in an older Korean population: a cross-sectional study. J Affec Disord. 2016;189:357–364.
 
30.
Vidgren M, Virtanen JK, Tolmunen T, et al. Serum concentrations of 25-hydroxyvitamin D and depression in a general middle-aged to elderly population in Finland. J Nutr Health Aging. 2018;22(1):159–164.
 
31.
Pu D, Luo J, Wang Y, et al. Prevalence of depression and anxiety in rheumatoid arthritis patients and their associations with serum vitamin D level. Clin Rheumatol. 2018;37(1):179–184.
 
32.
Jaaskelainen T, Knekt P, Suvisaari J, et al. Higher serum 25-hydroxyvitamin D con- centrations are related to a reduced risk of depression. Br J Nutr. 2015;113(9):1418–1426.
 
33.
Milaneschi Y, Hoogendijk W, Lips P, et al. The association between low vitamin D and depressive disorders. Mol Psychiatry. 2014;19(4):444–451.
 
34.
Sherchand O, Sapkota N, Chaudhari RK, et al. Association between vitamin D deficiency and depression in Nepalese population. Psychiatry Res. 2018;267:266–271.
 
35.
Briggs R, McCarroll K, O’Halloran A, et al. Vitamin D deficiency is associated with an increased likelihood of incident depression in community-dwelling older adults. J Am Med Dir Assoc. 2019;20(5):517–523.
 
36.
Karonova TL, Andreeva AT, Beljaeva OD, et al. Anxiety/depressive disorders and vitamin D status. Zh Nevrol Psikhiatr Im SS Korsakova. 2015;115(10 Pt 2):55–58.
 
37.
Han B, Zhu FX, Yu HF, et al. Low serum levels of vitamin D are associated with anxiety in children and adolescents with dialysis. Sci Rep. 2018;8(1):5956.
 
38.
Bossola M, Ciciarelli C, Di Stasio E, et al. Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. Gen Hosp Psychiatry. 2010;32(2):125–131.
 
39.
Can MS, Baykan H, Baykan O, et al. Vitamin D levels and vitamin D receptor gene polymorphism in major depression. Psychiatr Danub. 2017;29(2):179–185.
 
40.
Huang JY, Arnold D, Qiu CF, et al. Association of serum vitamin D with symptoms of depression and anxiety in early pregnancy. J Women’s Health. 2014;23(7):588–595.
 
41.
Zhao G, Ford ES, Li C, Balluz LS. No associations between serum concentrations of 25-hydroxyvitamin D and parathyroid hormone and depression among US adults. Br J Nutr. 2010;104(11):1696–1702.
 
42.
Almeida OP, Hankey GJ, Yeap BB, et al. Vitamin D concentration and its association with past, current and future depression in older men: the health in men study. Maturitas. 2015;81(1):36–41.
 
43.
Kwasky AN, Groh CJ. Vitamin d, depression and coping self-efficacy in young women: longitudinal study. Arch Psychiatric Nur. 2014;28(6):362–367.
 
44.
Michaelsson K, Melhus H, Larsson SC. Serum 25-hydroxyvitamin D concentrations and major depression: a mendelian randomization study. Nutrients. 2018;10(12):1987.
 
45.
de Koning EJ, Lips P, Penninx BWJH, et al. Vitamin D supplementation for the prevention of depression and poor physical function in older persons: the D-Vitaal study, a randomized clinical trial. Am J Clin Nutr. 2019;110(5):1119–1130.
 
46.
Khoraminya N, Tehrani-Doost M, Jazayeri S, et al. Therapeutic effects of Vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder. Aust N Z J Psychiatry. 2013;47:271–275.
 
47.
Zhu C, Zhang Y, Wang T, et al. Vitamin D supplementation improves anxiety but not depression symptoms in patients with vitamin D deficiency. Brain Behav. 2020;10(11):e01760.
 
48.
Kaviani M, Nikooyeh B, Zand H, et al. Effects of Vitamin D supplementation on depression and some involved neurotransmitters. J Affect Disord. 2020;269:28–35.
 
49.
Mozaffari-Khosravi H, Nabizade, L, Yassini-Ardakani SM, et al. The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency: a randomized clinical trial. J Clin Psychopharmacol. 2013;33:378–385.
 
50.
Vellekkatt F, Menon V, Rajappa M, et al. Effect of adjunctive single dose parenteral vitamin D supplementation in major depressive disorder with concurrent vitamin D deficiency: a double-blind randomized placebo-controlled trial. J Psychiatr Res. 2020;129:250–256.
 
51.
Eid A, Khoja S, AlGhamdi S, et al. Vitamin D supplementation ameliorates severity of generalized anxiety disorder (GAD). Metab Brain Dis. 2019;34:1781–1786.
 
52.
Hansen JP, Pareek M, Hvolby A, et al. Vitamin D3 supplementation and treatment outcomes in patients with depression (D3-Vit-Dep). BMC Res Notes. 2019;12(1):1–6.
 
53.
Bertone-Johnson ER, Powers SI, Spangler L, et al. Vitamin D supplementation and depression in the women’s health initiative calcium and vitamin D trial. Am J Epidemiol. 2012;176(1):1–13.
 
eISSN:2084-6312
ISSN:1505-7054
Journals System - logo
Scroll to top